Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02990481 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Toray Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02990481 is a Phase 1 study that has completed, run by Toray Industries. The registered enrollment target is 38 participants.
The verdict
NCT02990481, a Phase 1 study, has completed, sponsored by Toray Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies
Interventions
- BIOLOGICAL TRK-950
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2019-09-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02990481
The ClinicalTrials.gov registry entry for NCT02990481 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Toray Industries, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRK-950 is the first listed.
NCT02990481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02990481 about?
NCT02990481 is a clinical study titled "A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors". 1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies
What is the current status of trial NCT02990481?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2017-03-06. Estimated completion is 2019-09-16.
What interventions are being tested in trial NCT02990481?
The interventions under investigation include: TRK-950 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02990481?
This trial is sponsored by Toray Industries, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.